Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy

3. Auflage 2025
ISBN: 978-0-443-27356-8
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 216 mm x 276 mm

Handbook of Brain Tumor Chemotherapy, Molecular Therapies, and Immunotherapy, Third Edition offers a unique cutting-edge collection of basic science and clinical information brain tumor chemotherapy research. This book represents the most complete single-volume resource available for information on the subject of brain tumor chemotherapy. Including a multidisciplinary approach, this volume combines recent advances tumor therapy with molecular biology, molecular therapeutics, immunobiology, and immunotherapy approaches in one location. Chapters new to this volume include cutting-edge research on the molecular underpinnings of brain tumors such as glioblastoma and other gliomas and the targeted molecular therapies to consider for treatment.

Autoren/Hrsg.

Newton, Herbert B.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Chemotherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie

Inhaltsverzeichnis

SECTION 1: PHARM AND CLIN APPLICA
1. Overview and Path PBT/MBT
2. Clin Pharm of BT Chemo (and PK/PD)
3. Chemo/Drug Interactions
4. Pre-Clin Chemo Develop
5. Microarray Analysis and Proteomics
6. Methylation Analysis
7. Next Generation Sequencing
8. Liquid Biopsy
9. RNA Sequencing
10. Chemo Resistance
11. Clinical Trial Design
12. Biology of BBB and BTB

SECTION 2: INNOVATIVE CHEMO DELIV
13. IA Chemotherapy
14. BBBD Chemo
15. Interstitial Chemo
16. Intratumoral Chemo and CED
17. BMTP Chemo
18. Intrathecal Chemo of BT’s
19. Gene/Viral Tx Approaches
20. Nanoparticles/Drug Delivery BT’s

SECTION 3: MOLEC BIOL AND MOLEC THERAPEUTICS
21. Mol Genetics of BT’s
22. Cell Cycle Regulation
23. Cell Cycle Therapy
24. Apoptosis and Chemo
25. Growth Factor Signaling and Tx
26. Ras/RAF/MEK/ERK Signaling and Tx
27. PI3K, AKT, mTOR and Tx
28. HGF/C-MET and Tx
29. NTRK Pathway and Tx
30. SHH Signaling Pathway and Tx
31. Angiogenesis and Angio I’s
32. Bevacizumab and BT’s
33. HDAC Inhibitors and BT’s
34. Cancer Neuroscience and BT’s

SECTION 4: CHEMO SPECIFIC TUMORS - ADULTS
35. Chemo of HG Astro’s - traditional
36. Chemo of HG Astro’s
37. Molecular Tx HG Astro’s
38. Chemo of LG Astro’s
39. Chemo of Oligo’s
40. Chemo of PCNSL
41. Chemo of Medullo - adult
42. Chemo of Ependymoma - adult
43. Chemo of Neuronal Tumors
44. Chemo of Schwannomas
45. Chemo of Pineal Tumors
46. Chemo of Meningioma
47. Trad chemo of Brain Metastases
48. Molecular approaches Brain Mets

SECTION 5: CHEMO SPECIFIC TUMORS - PEDIATRICS
49. Chemo of Pediatric Low-Grade Gliomas
50. Chemo of Pediatric High-Grade Gliomas
51. Chemo of Medullo - childhood
52. Chemo of Brainstem Glioma
53. Chemo of CNS Germ Cell Tumors
54. Chemo of Ependymoma - childhood
55. Chemo of CNS AT/RT
56. Chemo of CNS PNET
57. Chemo of Choroid Plexus CA

SECTION 6: IMMUNOTHERAPY OF BT’S
58. Overview Immune/Checkpoints
59. Checkpoint I’s BT’s
60. Overview DC Vaccines BT
61. Overview EGFR vaccines BT
62. Overview Vaccines - Peds

SECTION 7: RESPONSE ASSESSMENT, QUALITY OF LIFE, AND NEUROPSYCH
63. Issues Response Assess BT chemo
64. Path and MRI Pseudo-Progression
65. RANO
66. iRANO
67. Overview QOL Assess N-O
68. Neuropsych Chemo Tx

Über Autor(innen)

Newton, Herbert B.
Dr. Newton is currently the Director of the Neuro-Oncology Center and CNS Oncology Program at the Advent Health Cancer Institute and Advent Health Orlando Campus. He recently retired as Professor of Neurology and Neurosurgery at the Ohio State University Medical Center and the James Cancer Hospital, and was the holder of the Esther Dardinger Endowed Chair in Neuro-Oncology. He trained in Neuro-Oncology with Drs. Jerome Posner and William Shapiro at Memorial Sloan-Kettering Cancer Center in New York, and since then had been in academic Neuro-Oncology for over 25 years. He has published more than 220 peer-reviewed articles and book chapters, and is the Chief Editor or Co-Editor of ten textbooks in the field of Neurology and Neuro-Oncology. In addition, he has been listed as a Best Doctor (Neurology) and Top Doctor for Cancer (Neuro-Oncology) for the past 18 years.